323 related articles for article (PubMed ID: 33586253)
1. Human induced pluripotent stem cells and CRISPR/Cas-mediated targeted genome editing: Platforms to tackle sensorineural hearing loss.
Stojkovic M; Han D; Jeong M; Stojkovic P; Stankovic KM
Stem Cells; 2021 Jun; 39(6):673-696. PubMed ID: 33586253
[TBL] [Abstract][Full Text] [Related]
2. A human induced pluripotent stem cell-based modular platform to challenge sensorineural hearing loss.
Zine A; Messat Y; Fritzsch B
Stem Cells; 2021 Jun; 39(6):697-706. PubMed ID: 33522002
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
Zhang Y; Sastre D; Wang F
Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
[TBL] [Abstract][Full Text] [Related]
4. Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.
Gu X; Wang D; Xu Z; Wang J; Guo L; Chai R; Li G; Shu Y; Li H
Genome Biol; 2021 Mar; 22(1):86. PubMed ID: 33752742
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Kim EJ; Kang KH; Ju JH
Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
[TBL] [Abstract][Full Text] [Related]
6. Design and Validation of CRISPR/Cas9 Systems for Targeted Gene Modification in Induced Pluripotent Stem Cells.
Lee CM; Zhu H; Davis TH; Deshmukh H; Bao G
Methods Mol Biol; 2017; 1498():3-21. PubMed ID: 27709565
[TBL] [Abstract][Full Text] [Related]
7. The application of genome editing in studying hearing loss.
Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
[TBL] [Abstract][Full Text] [Related]
8. Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review).
Alagoz M; Kherad N
Int J Mol Med; 2020 Aug; 46(2):521-534. PubMed ID: 32467995
[TBL] [Abstract][Full Text] [Related]
9. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
11. Potential of Gene and Cell Therapy for Inner Ear Hair Cells.
Lee MY; Park YH
Biomed Res Int; 2018; 2018():8137614. PubMed ID: 30009175
[TBL] [Abstract][Full Text] [Related]
12. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
13. CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
Chaterji S; Ahn EH; Kim DH
Theranostics; 2017; 7(18):4445-4469. PubMed ID: 29158838
[TBL] [Abstract][Full Text] [Related]
14. CRISPR editing in biological and biomedical investigation.
Huang J; Wang Y; Zhao J
J Cell Physiol; 2018 May; 233(5):3875-3891. PubMed ID: 28786481
[TBL] [Abstract][Full Text] [Related]
15. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
[TBL] [Abstract][Full Text] [Related]
16. Advances in genome editing for genetic hearing loss.
Ding N; Lee S; Lieber-Kotz M; Yang J; Gao X
Adv Drug Deliv Rev; 2021 Jan; 168():118-133. PubMed ID: 32387678
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-Mediated Fluorescent Tagging of Endogenous Proteins in Human Pluripotent Stem Cells.
Sharma A; Toepfer CN; Ward T; Wasson L; Agarwal R; Conner DA; Hu JH; Seidman CE
Curr Protoc Hum Genet; 2018 Jan; 96():21.11.1-21.11.20. PubMed ID: 29364519
[TBL] [Abstract][Full Text] [Related]
18. Current development of patient-specific induced pluripotent stem cells harbouring mitochondrial gene mutations and their applications in the treatment of sensorineural hearing loss.
Chou CW; Hsu YC
Hear Res; 2023 Mar; 429():108689. PubMed ID: 36649664
[TBL] [Abstract][Full Text] [Related]
19. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
20. Efficient introduction of an isogenic homozygous mutation to induced pluripotent stem cells from a hereditary hearing loss family using CRISPR/Cas9 and single-stranded donor oligonucleotides.
Dong Y; Peng T; Wu W; Tan D; Liu X; Xie D
J Int Med Res; 2019 Apr; 47(4):1717-1730. PubMed ID: 30819013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
